|Day's Range||0.67 - 0.70|
|52 Week Range||0.36 - 2.67|
|PE Ratio (TTM)||-1.28|
|Earnings Date||Jul 27, 2017 - Jul 31, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
LOS ANGELES, June 13, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Shanta Chawla, M.D., who ...
NEW YORK, NY / ACCESSWIRE / June 9, 2017 / CytRx's shares saw a big gaining day yesterday after the company announced a big regulatory pathway update about aldoxorubicin, a tumor-targeted doxorubicin conjugate ...
LOS ANGELES, June 8, 2017 /PRNewswire/ -- CytRx Corporation (CYTR) a biopharmaceutical research and development company specializing in oncology, today announced an update on the regulatory pathway for a New Drug Application (NDA) submission for aldoxorubicin in soft tissue sarcomas (STS). The Company plans to submit a rolling NDA under section 505(b)(2) to the FDA for aldoxorubicin as a treatment for STS. The 505(b)(2) pathway is designed for a new drug that contains the same active ingredient as a previously approved drug, also known as a reference drug. For aldoxorubicin, doxorubicin is the reference drug. The NDA submission is not reliant solely on the recently completed Phase 3 clinical trial in STS or overall survival results. Rather, CytRx's completed pharmacokinetic clinical trial, Phase 2b and Phase 3 trials in STS, along with preclinical safety and efficacy studies, will serve as "scientific bridges" between aldoxorubicin and doxorubicin.